US drug manufacturer Eli Lilly has completed its acquisition of radiopharmaceutical company Point Biopharma for approximately $1.4 billion.

Bayer and UK biotech Bicycle Therapeutics have agreed to collaborate to develop and commercialize the latter’s radioconjugates for multiple oncology targets.

Ariceum Therapeutics, a Berlin-headquartered private biotech developing radiopharmaceutical products for the diagnosis and systemic targeted certain hard-to-treat cancers...